Genpharmasec Ltd (GENPHARMA) — shareholding pattern, promoter holding, financials and share price
About Genpharmasec Ltd (GENPHARMA)
Genpharmasec Ltd operates in the Trading & Distributors industry, within the Services sector. It trades on the NSE as GENPHARMA and on the BSE under scrip code 531592. Its ISIN is INE861N01036.
Incorporated in 1992, Generic Pharmasec Ltd deals in pharmaceutical activities /services and trades in equity shares [1]
Genpharmasec Limited, established in 1992, is primarily engaged in pharmaceutical activities and trading in equity shares, initially focusing on chemicals and pigments manufacturing.
The company pivoted in 2018 towards pharmaceuticals and ventured into securities trading, marking a strategic shift in operations.
Listed peers in Trading & Distributors: Chandni Machines Ltd, Constronics Infra Ltd, Bombay Cycle & Motor Agency Ltd, Eforu Entertainment Ltd, Danube Industries Ltd, Dhanlaxmi Cotex Ltd.
Valuation & Returns
10 Jul 2026At ₹1.11 a share on 10 Jul 2026, Genpharmasec Ltd (GENPHARMA) was valued at a price-to-earnings ratio of 109.76x against an industry P/E of 21.24x and a price-to-book of 0.94x on a book value of ₹1.18 per share as of Mar 2025. Solomo computes return on equity of 0.86% and return on capital employed of 3.14% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 109.76x
- Industry P/E
- 21.24x
- P/B
- 0.94x
- EPS (TTM)
- ₹0.01
- Book value / share
- ₹1.18
- ROE
- 0.86%
- ROCE
- 3.14%
- ROA
- 0.7%
- Debt / equity
- 0.08x
- Dividend yield
- 0%
- EBITDA margin
- 3.12%
- 52-week range
- ₹0.75 – ₹2.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Genpharmasec Ltd (GENPHARMA) reported revenue of ₹140 crore, net profit of ₹1 crore and earnings per share of ₹0.03. That compares with revenue of ₹34 crore and net profit of ₹1 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹55.43 crore and net profit ₹1.36 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 26 | 30 | 34 | 140 |
| Net profit (₹ cr) | 1 | 0 | 1 | 1 |
| EPS (₹) | 0.02 | 0 | 0.02 | 0.03 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | - | 14.84% | 6.46% | 10.88% |
| Profit growth | 42.96% | 19.59% | - | 823.53% |
| Stock price CAGR | 21% | -29% | -20% | -50% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 29.98% of Genpharmasec Ltd (GENPHARMA) (unchanged from the previous quarter). Market capitalisation was ₹61 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: RUSHABH SEVANTILAL SANGHAVI 4.42%, HUF 3.86%, SADASHIV KANYANA SHETTY 2.06%, YOGESHKUMAR RASIKLAL SANGHAVI 1.77%, VISHESH MAHESH NIHALANI 1.52%, L7 HITECH PRIVATE LIMITED 1.17%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 29.98% | - | - | - | 70.02% |
| Mar 2026 | 29.98% | - | - | - | 70.02% |
| Dec 2025 | 29.98% | - | - | - | 70.02% |
| Sep 2025 | 29.98% | - | - | - | 70.02% |
| Jun 2025 | 29.98% | - | - | - | 70.02% |
| Mar 2025 | 29.98% | - | - | - | 70.02% |
| Dec 2024 | 29.98% | - | - | - | 70.02% |
| Sep 2024 | 29.98% | - | - | - | 70.02% |